MTOR and gastric cancer: Capasso et al. tested in vitro the effects of several inhibitors, such as erlotinib (EGFR inhibitor), the MEK inhibitor (BAY-86-9766), trastuzumab (HER2 inhibitor), and GDC-0980 (PIK3K/mTOR inhibitor) alone or in combination on various types of GC cells.